Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Summary

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumor, Adult
• Colorectal Cancer
• Non Small Cell Lung Cancer
• Pancreatic Cancer
• CRC
• NSCLC
• Pancreas Cancer
• Mesothelioma
• Ovarian Cancer
• Ovarian Neoplasms
• Ovarian Carcinoma
• Mesothelioma, Malignant
• Mesothelioma; Lung
• Cancer
• Triple Negative Breast Cancer (TNBC)
• Renal Cell Carcinoma (Kidney Cancer)
• Head and Neck Squamous Cell Carcinoma HNSCC

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

A2 Biotherapeutics Inc.

Last updated on ClinicalTrials.gov

September 25, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites